India, Aug. 12 -- image credit- shutterstock

Cohance Lifesciences Limited,formerly Suven Pharmaceuticals, a partner of choice for global innovator pharma companies, has announced Rs 23 crore investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

This strategic investment strengthens the CRDMO's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities.

Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the company to take these high-value chemistries from laboratory ...